DOI: 10.12890/2026_007288

Scleroedema preceding monoclonal gammopathy by 30 years

Authors

  • Ami Schattner The Faculty of Medicine, Hebrew University and Hadassah Medical School, Jerusalem, Israel

amischatt@gmail.com

Keywords

Scleroedema, monoclonal gammopathy of undetermined significance (MGUS), myeloma, beta-2 microglobulin, complement component 4 (C4)

Abstract

Three decades after the diagnosis of scleroedema (Buschke’s disease), a benign chronic sclerotic skin condition of unknown pathogenesis without systemic involvement, a patient developed secondary gout and normocytic anaemia. Investigations revealed monoclonal gammopathy of undetermined significance, with 1.3 g/dl immunoglobulin G-lambda in the gamma region, a clinically important albeit rare scleroedema-related manifestation, with associated low complement component 4 levels and Coomb’s positivity, but no myeloma or amyloidosis.

View the entire article

Downloads

References

  1. Knobler R, Geroldinger-Simic M, Kreuter A, Hunzelmann N, Moinzadeh P, Rongioletti F, et al. Consensus statement on the diagnosis and treatment of sclerosing diseases of the skin, Part 2: Scleromyxoedema and scleroedema. J Eur Acad Dermatol Venereol. 2024;38:1281-99. doi: 10.1111/jdv.19937.
  2. Rongioletti F, Kaiser F, Cinotti E, Metze D, Battistella M. Calzavara-Pinton PG, et al. Scleredema. A multicentre study of characteristics, comorbidities, course and therapy in 44 patients. J Eur Acad Dermatol Venereol. 2015;29:2399-404. doi: 10.1111/jdv.13272.
  3. Cole GW, Headley J, Skowsky R. Scleredema diabeticorum: a common and distinct cutaneous manifestation of diabetes mellitus. Diabetes Care. 1983;6:189-92. doi: 10.2337/diacare.6.2.189.
  4. Tawanwongsri W, Eden C. Management and clinical outcomes of scleredema diabeticorum: a scoping review. Diseases. 2025;13:346. doi: 10.3390/diseases13100346.
  5. Mir TH, Patell R, Freed JA, Santos-Patarroyo SD, Jabeen B. Monoclonal gammopathies of cutaneous significance: A nomenclature and pathophysiology-based classification. J Am Acad Dermatol. 2026;S0190-9622(26)00296-3. doi: 10.1016/j.jaad.2025.12.126.
  6. Hodak E, Tamir R, David M, Hart M, Sandbank M, Pick A. Scleredema adultorum associated with IgG-kappa multiple myeloma – a case report and review of the literature. Clin Exp Dermatol. 1988;13:271-4. doi: 10.1111/j.1365-2230.1988.tb00699.x.
  7. Roupie AL, Battistella M, Talbot A, Jachiet M, Bouaziz JD, Vignon-Pennamen MD, et al. Coexisting cutaneous macroglobulinosis and scleredema of Buschke in a patient with a Waldenstrom macroglobulinemia. J Europ Acad Dermatol Venereol. 2018;33:e104-6. doi: 10.1111/jdv.15268.
  8. Nickell AL, Corn M, Mannuru D Hinze AM. Scleredema in the setting of monoclonal gammopathy of unknown significance with progression to multiple myeloma: a case report. Cureus. 2023;15(9):e44968. doi: 10.7759/cureus.44968.
  9. Kovary PM, Vakilzadeh F, Macher E, Zaun H, Merk H, Goerz G. Monoclonal gammopathy in scleredema. Observations in three cases. Arch Dermatol. 1981;117:536-9. doi: 10.1001/archderm.1981.01650090018016.
  10. Chang HK, Kim YC, Kwon BS. Widespread scleredema accompanied with a monoclonal gammopathy in a patient with advanced ankylosing spondylitis. J Korean Med Sci. 2004;19:481-3. doi: 10.3346/jkms.2004.19.3.481.
  11. Kergala BSDP, Herath HMMTB, Janappriya GHDC, Dissanayaka BS, Shyamini SC, Liyanagama DP, et al. Scleredema associated with immunoglobulin A-k smoldering myeloma: a case report and review of the literature. J Med Case Rep. 2019;13:145. doi: 10.1186/s13256-019-2072-1.
  12. Vetsiou E, Adams L, Philippidou M, Nambi R, Cuthill K, Basu TN. Scleredema of Buschke: 2 cases with a remarkable response to treatment of the underlying paraprotein. JAAD Case Rep. 2025;70:236-9. doi: 10.1016/j.jdcr.2025.12.033.
  13. Marcolongo D, Bressan A, Zanatta E, Alaibac MSA, Gianesello I, Binotto G, et al. Scleredema associated with IgG/κ monoclonal gammopathy of clinical significance successfully treated with Daratumumab monotherapy: a case report. EJHaem. 2026;7(2):e70262. doi: 10.1002/jha2.70262.
  14. Spitler LE, Spath P, Petz L, Cooper N, Fudenberg HH. Phagocytes and C4 in paraproteinaemia. Br J Haematol. 1975;29:279-92. doi: 10.1111/j.1365-2141.1975.tb01822.x.
  15. Kyle RA, Larson DR, Therneau TM, Dispenzieri A, Kumar S, Cerhan JR, et al. Long-term follow-up of monoclonal gammopathy of undetermined significance. N Engl J Med. 2018;378:241-9. doi: 10.1056/NEJMoa1709974.
  16. Rajkumar SV, Kumar S. Monoclonal gammopathy of undetermined significance. N Engl JMed. 2025;393:1315-26. doi: 10.1056/NEJMx260024.

Published

2026-10-16

Issue

2026: LATEST ONLINE

Categories

How to Cite

1.
Schattner A. Scleroedema preceding monoclonal gammopathy by 30 years. EJCRIM [Internet]. 2026 Oct. 16 [cited 2026 Nov. 3];13. Available from: https://ejcrim.com/index.php/ejcrim/article/view/7288

Most read articles by the same author(s)